A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

Clinical trial NCT07566052 · RECRUITING

Trial details

NCT number: NCT07566052
Sponsor: Astellas Pharma Global Development, Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer (NSCLC)

Start date: 2026-04-28
Primary completion: 2030-06-30
Enrollment: 356

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.